<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 63 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page62.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=63">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 63 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 63</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=63"><img src="../thumb/63.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>32 / 2020-04                                                        Central Nervous System - 1.5.4
   Indications: Behav.disturbs.in ac.& chron. schizophren., manic phase   ESPIRIDE, (Aspen Pharmacare: Pharma) Pharmacare [P/S]  libido, confusion.state, suicid.ideat./ behav., QT prolongat., ventricul.
   of bipol.affect.disord., ment.retardat.  Sulpiride.        fibrillat./tachycard., Torsade de Pointes, sudden unexplain.death,
   796751-005: 2 mg, 100, R139,66  Indications: React.depress.& depress.assoc.with psychos.of oth-  withdr. sympts. with abrupt discont
   789798-018: 10 mg, 100, R347,92  er origins, prophylax.& treatm.of depress. psychos., schizophren.,   Warnings and special precautions: Neurolept. malign.syndr.may
   Dosage: Indiv.dos.           ac.delir., ac. hallucinat.& confus.states, behav.disord., duod.ulc. of   occ., incr.mortal.observ.more oft. in pts.with pre-exist.organ.brain
   Ac.schizophren.& other ac.psychos., sev.ac. states of agi-  psychosomat.orig., vertigo, anti-emet.  syndr./ment. retardat./opiate & alcoh.abuse, indiv.sucept.to QT pro-
   tat., mania: 10-50 mg/day. Mod.to sev.cases: Init. 20 mg/day incr.if   (S5) CAPS, [P/S] Y/2.5/386.  longat. & pts.with hist.of CV disords./signif. bradycard./ recent MI//
   necess.by 10-20 mg/day every 2-3 days to 75 mg.  819654-019: 50 mg, 100, R208,12  uncompens.HF/card. dysrhythm., concomit.antipsychot.meds., de-
   Chron.schizophren.& other chron.psychos. Maint: Usually   Dosage: Reduc.dos.grad.bef.withdr.& in elderly  press. with incr.risk of suicide/suicidal thoughts/self harm, venous
   20-40 mg/day.                Schizophren: Adults: Init. 200-400 mg 2xdly. incr.if necess.to max.   thromboembol.may occ. & risk facts. to be identif.bef.& dur.treatm.,
   Agitat.in oligophren.pts: 6-20 mg/day. If necess. incr.to 25-  1,2 g 2xdly. Maint: 600-800 mg/day in div.dos.  elderly & debilit., Parkinson’s, sev.arterioscleros., senile confus., sev.
   40 mg dly.                   Mild psychiatr.condits.& behav.disords: Adults: Init. 100-  hepat./ren./CV/cerebrovasc./resp.dis., narrow. angle glauc., diab.
   (S5) ACUPHASE INJ, [P/S] W/2.6.5/27.  200 mg up to 300 mg dly.in div.dos., reduc./incr.as necess.for maint.   mellit., hypothyroid., myasthen. grav., prostat. hypertrophy, epilep.,
   Zuclopenthixol acet.         Childr.6-12 yrs: 3-5 mg/kg/day in div.dos.  phaeochromocyt., thioxanth./other antipsychot. hypersens., eff.on the
   Indications: Init.treatm.of ac.psychos.incl.mania, exacerbat.of   Gastro-enterol: Adults: 150-300 mg dly.in div.dos. Maint.& du-  vomit.centr.may mask sympts.of OD of other agents/disords.such as
   chron.psychos.               rat.as necess.                GI obstruct., reg.eye examin.advis., avoid.undue sun expos., monit.
   786934-018: 50 mg/ml, 1x1 ml amp, R126,54  Vertigo: Adults: 150-300 mg dly.in div.dos. depend. on intens.   haematolog.paramet.periodic., caut. in pts. with organ.brain syndr./
   Dosage: Admin. IMI.          Contraindications: Phaeochromocyt., bone marr. depress., hy-  convuls./adv.hepat. dis., insul.& gluc.respon.poss.modif. call.for adj.of
   Adults: Indiv.accord.to condit. Normal dos.range 50-150 mg, rep.if   poman., manic or pre-manic phase of manic-depress.psychos.,   antidiabet.ther.in diabet.pts., concom.meds known to cause electrol.
   necess.with 2-3 day time interv. Few pts.may req.an addit.inj.24-48   ac.mania., concom.meds. caus. leucopen., ac. porphyr., safety in   disturbs, concom.meds incr. flupentixol.plasma conc.
   hrs.follow.1st inj. Maint: Change to Clopixol Depot.  pregn.not est.  Drug interactions: May.potent.sedat.eff.of alchol., may potent.eff.
   Contraindications: Ac.alcoh., barbit./opiate intoxicat., hepat.dis.,   Side effects: Sedat., extrapyramid.sympt., sleep disturb., overstimu-  of barbits./CNS depress., may incr./reduc.eff.of antihypertens.meds.,
   comat.states., preg.& lactat., dementia-relat. behav.disturbs., childr.  lat., agitat., hyperten., fatig., impot., menstr.irreg., galactorrh., mass   incrrisk of neurotoxic.with comncom.Li., concom.TAD’s may mutually
   Side effects: Thrombocytopen., neutropen., leukopen., agranulocy-  gain, antimuscar.eff., CNS effs., nas.congest., tachycard., ECG chang.,   inhib.metab.of both meds., eff.of levodopa/ adrenerg.meds reduc,
   tos., hypersens./ anaphylact. reacts., hyperprolactinaem., incr/decr.  postur.hypotens., vis. disturbs., ejaculat.inhib., allerg.reacts., deposit.  may potent. adverse eff.of antimuscarin., metoclopram. piperazine
   appet., incr./ decr. weight, hyperglycaem., imp.gluc.tol., hyperlipi-  of pigm. in skin & eyes with prolong.ther., corn.& lens opacit., photo-  incr.risk of extrapyramid.disord., incr. QT interv.relat.to antipsych.
   daem., insomn., depress., anx., nervousn., abnorm. dreams, agitat.,   sens., bld.dyscras., alter.endocr.& metabol. functs., imp.body temp.  treatm.poss. exacerbat. by concom. meds.known to signif.incr.QT
   incr./decr.libido, apathy, nightmares, confus.state, somnol, akathis.,   regulat., may mask sympts.of GI obstruct.  interv. incl. quinidine/amiodarone/sotalol/dofetilide/ thioridazine/
   hyper-/hypokines., trem., dyston., hyperton., dizzin., headache, par-  Special precautions: Hypertens., CV/resp.dis., condits.where sudd.  erythromycin/astemizole/ gatifloxacin/ moxifloxacin/cisapride/Li
   aesthes., attent.disturbs., amnes., abnorm. gait, tard.dyskines., hy-  drop in BP undesir., adjust dos.if used in conjunct.with other meds.  See also MDR page 485.
   perreflex, dyskines., parkinson., syncope, atax., speech disord., hy-  likely to cause postur.hypotens., exist.tachycard./card. insuff., liv.dys-  FLUANXOL DEPOT, Lundbeck [P/S]
   poton., convuls., migraine, neurolept.malign. syndr., accommodat.  funct., jaund.hist., Parkinson., anti-convuls. Ther., elderly, debilitat.,
   disord., abnorm.vision., oculogyrat., mydrias., vertigo, hyperacus.,   monit.sympts.for onset of agranulocytos.& instit.WBC counts if pres.,   Flupentixol decanoate.
                                                              Indications: Schizophren.
   tinnit., tachycard., palpit., ECG QT prolong., hypotens., hot flush,   reg.ophthalm.examin.in prolong.ther., cont. lact.& sorbit.& sweetn.
   ven.thromboembol., nasal congest., dyspn., GI disords., abnorml LFT,   Drug interactions: Anti-Parkinson.acts.of levodopa dimin., bio-  (S5) INJ. G/2.6.5/138
                                                              726672-004: 20 mg/ml, 1 x 1 ml, R84,75
   cholestat.hepatit., jaund., hyperhidros., prurit., rash, photosens., pig-  avail.reduc.by sucralfate/ antacids contain.Al & Mg hydroxid., en-  726672-025: 20 mg/ml, 5 x 1 ml, R423,79
   mentat. disord., seborrh.dermatit., purpura, myalg., musc. rigid., trism.,   hanc. anticholinerg.propert.of atrop.& TCA’s, antihypertens. act.of   Dosage: Deep IMI 20-60 mg every 2-4  wks. depend.on respons.
   torticoll., micturit.disord., urin.retent., polyur., neonat.drug withdraw.  adrenerg.neur.block.meds. reduc., enhanc.activ.of CNS depress.,   Contraindications: Extrem.excitab.& overactiv. pts., circulatory col-
   syndr., ejaculat.fail, erect.dysfunct., fem.orgasm.disord., vulvovagin.   may low. convuls. thresh.
   dryn., gynaecomast., galactorrh., amenorrh., priapism, asthen., fatig.,   ETOMINE, Pharmaco [P/S]  lapse, depress.consciousn., coma, pregn.& lactat., phaeochromocyt.,
                                                              bone marr. suppress.
   malaise, pain, thirst, hypotherm., pyrex., ventric.arrhythm./-fibrillat./-  Clothiapine
   tachycard., Torsade de Pointes, sudd.unexplain. death. Depot & Acu-  Indications: Ac.schizophren.psychos., depress. excitat.& neu-  Side effects: Extrapyramid.reacts., tard. dyskines., tachycard., pal-
                                                              pitat., bld.dyscras., somnol., akathis., hyper-/hypokines., trem., dys-
   phase: Inj.site reacts.      rot.sympt.
   Warnings and special precautions: Neurolept. malign.syndr.,   (S5) TABS, [P/S] A/2.6/730.  ton., dizzin., headache, tard.dyskines., dyskines., Parkinson., speech
                                                              disord., convuls., NMS, accommodat. disord., abnorm.vis., oculogy-
   convuls.disords., advanc. hepat./ ren./ CV dis., poss.dos.adjustm.  724777-008: 40 mg, 100, R1 376,49  rat., dyspn., GI disturbs., micturit.disord., urin. retent., neonat. withdr.
   of antidiabet.ther. as insul./gluc.respon.poss modif., monit.pts on   Dosage: Init: 120-160 mg (3-4 tabs.) dly.in 2-3 div. dos. Follow-up &   syndr., hyperhidros., prurit., skin rash, photosens., dermatit., myalg.,
   long-term ther.& eval.periodic., pts.suscept.to QT prolongat./with   maint: reduc.dly.dos.grad.to 40 mg or more rarely 80 mg.  musc. rigid., hyperprolactinaem., incr.appet.& weight, decr. appetit.,
   CV disord. hist., concom.meds. known to incr.QT interval/risk of card.  (S5) INJ, [P/S] A/2.6/729. 40 mg/4 ml.  hyperglycaem., abnorm. gluc. tol., hypotens., hot flushes, ven. throm-
   dysrhythm., avoid concom.anti-psychot.meds., identify poss VTE risk   724785-019: 10x4 ml, R900,31  boembol., asthen., fatig., inj.site reacts., abnorm. LFT, jaund., ejaculat.
   factors bef./dur.treatm.& undertake preventat. meas., stroke risk fac-  Dosage: Init: 120-160 mg (3-4 amps.) dly.IM/IV in 2-3 div.dos. In   fail., erect. dysfunct., gynaecomast., galactorrh., amenorrh., insomn.,
   tors, older pts.with dementia, withdraw.sympts.with abrupt.discont.,   sev.excitat.high.dos.may be admin. on 1  day. Max.dly dos: 360 mg   depress., nervousn., agitat., decr.libido, confus. state, QT prolongat.,
                                                 st
   tabs. contain hydrogen.castor oil & may cause GI disturbs., use in   in div.dos.in ac. excitat.  ventric.dysrhythm./-fibrillat./ -tachycard., Torsade de Pointes, sudd.
      rd
   pregn.3 trimest poss. result in extrapyram./ withdraw.sympts in   Contraindications: Comatose states, sev.CNS depress., large dos.&   unexplain. death, withdr.sympts.with sudd. discont.
   newborn., depot inj.with other meds.known to have myelosuppress.   abrupt dos.chang.in pts. suscept. to convuls., ac.alcoh.intox., safety in
   potent. Tabs: Lact.intol     pregn. & lactat.not est., no clinic.exper.in pts.und. 16 yrs.  Warnings and special precautions: Poss. developm. of neuro-
                                                              lept.malign.syndr., incr. mortality with pre-exist.organ.brain,syndr./
   Interactions: Enhanc.respon.to alcoh., barbit.& other CNS depress.,   Side effects: Labile BP & body temp., dry mouth, vis.disturb., or-  ment. retardat.& opiate and alcoh.abuse, eval longterm ther.to
   antihypertens.eff.of guanethid. block., low.eff.of levodopa & adren-  thostat.hypotens., extrapyramid. sympt., sedat, agitat., confus., hy-  determ.maint.dos., indiv.suscept.to QT prolongat. & hist.of CV dis-
   erg. drugs, metoclopramide & piperazine incr.risk of extrapyramid.  perkines., EEG chang., oed., rash, hyperpyrex., sweat., GI disturbs.,   ords.eg.QT prolong./ signif. bradycard./rec.ac.MI/uncompensat.HF
   sympt., TCA & neurolept.mutual. inhibit. the metabol.of each other.,   thrombocytopen.  & card. dysrhythm.,avoid other concom.antipsychot. treatm., eval.
   incr.neurotox. risk with concom.use of neuroleptics & Li., decr. clear.   Special precautions: Avoid inter-arter.inj., low. init.dos.for under-  VTE risk fact.& take prevent.meas., incr. CVA risk & incr.mortal.seen
   with CYP2D6 inhibits.        weight pts., kidn.dis., CV dysfunct., cerebr.vasc.insuff.& cerebr.scle-  in dement. particip.in clinic.trials.with some antipsychot., stroke risk
   EGLONYL, Sanofi-Aventis [P/S]  ros. incr. grad, monit.circulat.in elderly, thrombos., prostat. enlargem.,   fact., do not use for dement.-relat. behav. disturbs., liv.& card.dis.,
   Sulpiride                    glauc., paralyt.ileus, epilep.& postencephalit. states, convuls.suscept.  dysrhythm., sev. resp.dis., ren.fail., epilep., Parkins.dis., narr. angle
                                Drug interactions: Potents.centr.eff.of sedat., analgesic., hyp-
   Indications: Managem.of ac.schizophren.episod. & prev.ac.relapse   glauc., prostat.hypertrophy, hypo-/hyperthyroid., myasth.grav., thi-
   in chron.case.               not., antihistamin., narcot.& MAOI, act.of antihypertens.enhanc.,   oxanthenes./ other antipsychot.hypersens., convuls., advanc. hepat.
                                Li toxic.enhanc.
   (S5) CAPS, C/2.6.5/120                                     dis., modif.insul.& gluc.respons., reg.eye examinat., avoid sunlight
   722375-026: 50 mg, 100, R382,36  FLUANXOL, Lundbeck [P/S] &  expos., monit. haematolog. paramet.
   Dosage: Init. 200-800 mg oral 8/12 hrly over 24 hrs.in div.dos. x1-6   Flupenthixol dihydrochlor.  Drug interactions: Sedat.effs.of alcoh.& CNS depress. enhanc.,
   wks. Maint: 600-800 mg/day in div.dos.   Indications: Mild to mod.depress.with/out anx.  antihypertens.effs.eith.incr./ reduc., incr.neurotox.risk with concom.
   Contraindications: Porphyr., hypoman., manic/ pre-manic depress.   (S5) TABS. B/2.6.5/1372,1380.  Li, TCA & fluanxol depot inhib.metab.of one another, levodopa & adr-
   psychos., ac.mania, phaeochromocyt., concom.anti-Parkinson dopa-  726656-003: 0,5 mg, 30, R232,70  energ.effs.reduc., incr. extrapyramid. disord.with metoclopram.& pip-
   minerg. agents./prolactin-depend.tumours., congenit.QT prolongat.,   726664-006: 1 mg, 30, R327,94  erazine, antipsychot.relat.QT interv.incr. exacerbat. by agents known
   Parkinson’s dis., safety & effic.in childr.not est., safety in pregn.&   Dosage: Adults: Init. 1 mg as sngl.morn.dos., may be incr.to 2 mg   to incr.QT interv., meds. known to cause electrol.disturbs./plasma
   lactat. not est., breastfeed.  aft.1 wk.if respons.inadeq. Dly. dos. of more than 2 mg should be in   conc. incr.flupentixol plasma conc.
   Side effects: Hypertherm., neurolept.malign. syndr., sedat., extrapyr-  div.dos.to max. of 3 mg with last dos.to be giv.no later than 16h00. If   MOLIPAXIN, Sanofi-Aventis (Pty) Ltd
   amid.sympt., sleep disturb., overstimulat., agitat., parkinsonism, trem.,   no eff.observ.at max.dos.within 1 wk. withdr. medicat.  See Section 1.4.10
   hyperton., hypokines., hypersalivat., ac.dyskines., dyston., akathis.,   Elderly: Init. 0.5 mg as sngl.morn.dos., may be incr. to 1 mg aft.1 wk.if
   tard.dyskines., akinet. with/without hyperton., hyperkinet.-hyerton./   respons.inadeq. Exerc.caut. in furth.incr.dos.but ocass.pts. may req.  SULPIRIDE 50 OETHMAAN, Oethmaan Biosims [P/S]
   excitomot. syndr., postur.hypotens., QT-interv. prolongat., Torsades   dos.up to max.2 mg/day giv.in div.dos.in morn.& no later than 16h00  Sulpiride.
   de Pointes, hyperprolactinaem. dis., menstr. irreg., breast congest.,   Contraindications: Sev.depress.requir.ECT &/hospitalisat., ex-  Indications: React.depress.& depress.assoc.with psychos.of oth-
   galact., gynaecomast., impot., frigid., fatig., hypertens., mass incr.  citem./overactiv.incl.mania, pre-exist.CNS depress., coma, bone   er origins, prophylax.& treatm.of depress. psychos., schizophren.,
   Special precautions: Discont.treatm.in case of unexpl. hyper-  marrow suppress. or phaechromocyt., circulat.collapse., depress.  ac.delir., ac. hallucinat. & confus.states, behav.disord., duod.ulc.
   therm., verif.absence of factors which promote arrhythm.bef.admin.,   lev. of conciousn.due to any cause incl.sev.alcoh., barbit. & opiate   ther.adjunct, vertigo.
   ECG in init. eval. recomm., hypertens., concom.drugs with known   intoxicat., safety in pregn.& lactat. not est., not recomm.for childr.  (S5) CAPS, U/2.6.5/32
   postur.hypotens./sedat./ extrapyramid. S/E, ren. imp., elderly, epi-  Side effects: Tachycard., palpitats., bld.dyscras., somnolen., akathis.,   820199-028: 50 mg, 100, R164,20
   lep., psychot.suicid. cases.  hypo-/hyperkines., trem., dyston., dizzin., headache, tard.dyskines.,   Dosage: Elderly: Admin.in reduc.dos.
   Drug interactions: Incr.poss.of ventric. arrhythm. with antiarrhythm.  dyskines., Parkinson., speech disord., convuls., neurolept. malign.  Psychiatry:
   which prolong QT interv., enhanc. sedat.effs.with alcoh., enhanc. CNS   syndr., accommodat.disord., abnorm.vis., oculogyrat., dyspn., GI   Mild psych.condits.of short.durat.& behav. disords: Adults:
   depress. & antihypertens.eff., bradycard./ hypokaleam. induc.meds./  disords., micturit. disord., neonat.withdraw.syndr., urin. retent.,   Init. 100-150 mg dly. up to 300 mg dly. in div.dos. Maint: Reduc./incr.
   class Ia/class III antiarrhythm. agents/pimozide/sultopride/ haloperi-  hyperhidros., prurit., rash, photosens.react., dermatit., myalg.,   as necess. Treatm.durat: as necess. Withdr.grad. Sev.psych.disor-
   dol/ imipramine antidepress./Li/bepridil/ cisapride/ thioridazine/IV   musc. rigid., hyperprolactinaem., incr./decr. appetite, incr. weight,   ds:1200-1600 mg/day in div.dos. Psychiatry: Childr: 3-5 mg/kg bm.
   erythromyc./IV vincamine/ halofantrine/pentamidine & sparfloxacin   hyperglycaem., abnorm.glucose toler., hypotens., hot flush., venous   Gastro-enterol: Adults: 150-300 mg dly.in div. dos.
   poss induc.Torsades de Pointes.  thromboembol., asthen., fatig., hypersens., anaphylact. react.,   Vertigo: Adults: 150-300 mg dly.x15-20 days.
   Warnings: More freq.neurolept.malign.syndr.in cataton. schizo-  abnormal LFT, jaund., ejaculat.fail., erect. dysfunct., gynaecomast.,   Contraindications: Not recomm.in hypoman., manic or pre-manic
   phren.                       galactorrh., amenorrh., insomn., depress., nervousn., agitat., decr.  phase of manic-depress. psychos., ac.mania., pre-exist.CNS depress./</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page62.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page58.html">58</a>&nbsp;&nbsp;&nbsp;<a href="page59.html">59</a>&nbsp;&nbsp;&nbsp;<a href="page60.html">60</a>&nbsp;&nbsp;&nbsp;<a href="page61.html">61</a>&nbsp;&nbsp;&nbsp;<a href="page62.html">62</a>&nbsp;&nbsp;&nbsp;<a href="page63.html">63</a>&nbsp;&nbsp;&nbsp;<a href="page64.html">64</a>&nbsp;&nbsp;&nbsp;<a href="page65.html">65</a>&nbsp;&nbsp;&nbsp;<a href="page66.html">66</a>&nbsp;&nbsp;&nbsp;<a href="page67.html">67</a>&nbsp;&nbsp;&nbsp;<a href="page68.html">68</a>
             </td>
             <td width="35%"><a href="page64.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page64.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
